Hagerman Allison
VP, Product Development
Hagerman Allison has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Feb 13, 2026.
On the most recent filing, Hagerman Allison is listed as VP, Product Development at ONCOLYTICS BIOTECH INC. Inside the rolling window, Hagerman Allison reported 1 open-market purchase totaling $8K in ONCY and no open-market sales.
Companies traded
Other insiders at ONCY
Insider Buying
$8K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Hagerman Allison made?
Hagerman Allison has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Hagerman Allison trade?
Hagerman Allison has filed SEC Form 4 disclosures for 1 company, including ONCY.
When was Hagerman Allison's most recent SEC Form 4 filing?
Hagerman Allison's most recent SEC Form 4 filing on Tracefour is dated Feb 13, 2026.
What is Hagerman Allison's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Hagerman Allison is listed as VP, Product Development.
What is Hagerman Allison's total buy and sell value in the current window?
Inside the rolling retention window, Hagerman Allison bought $8K and sold $0 based on SEC Form 4 filings.
What was Hagerman Allison's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 10,000 ONCY shares on 2026-02-12, worth $8K, per SEC Form 4 filings.